Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetapir 18F Imaging in FTD, AD, and Controls
NCT01890343Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Sep 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Florbetapir in Alzheimer's disease (AD) and frontotemporal dementia (FTD) (3 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Qualitative Amyloid Image Assessment and Quantitative Amyloid Image Assessment. Started Sep 2009; status: completed.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT01890343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890343.